QUINCE THERAPEUTICS INC (QNCX)
US22053A1079 - Common Stock
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
Quince Therapeutics just reported results for the fourth quarter of 2023.
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
Quince Therapeutics Launches Scientific Advisory Board
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
Top Buys by Directors: Lamond's $601.5K Bet on QNCX
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Quince Therapeutics to Participate at Investor Events in January 2024
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
FDA lifts partial clinical hold on EryDel lead product EryDex (QNCX)
Quince Therapeutics said the FDA has lifted a partial clinical hold on the lead product of its merger partner, EryDel. Phase 3 testing is expected to begin after the deal closes.
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
Tuesday 9/5 Insider Buying Report: VAPO, QNCX
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
Quince stock falls on deal to buy EryDel SpA (NASDAQ:QNCX)
Quince Therapeutics (QNCX) traded lower pre-market Monday after announcing an agreement to acquire EryDel SpA, a privately held biotech based in Italy, for a combination of shares...
Echo Lake bumps up bid to buy Quince Therapeutics to $1.80/share (NASDAQ:QNCX)
Echo Lake Capital has raised its offer to acquire biotech firm Quince Therapeutics (QNCX) to $1.80 per share from its previous offer of $1.60, according to a July 13 letter sent to...
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor
Quince Therapeutics adopts poison pill amid unsolicited takeover offer
Quince Therapeutics (QNCX) said it adopted a limited duration shareholder rights plan and a dividend distribution after unsolicited acquisition proposal and accumulation of Quince shares...
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
Quince stock surges ~50% on acquisition offer from Echo Lake Capital (QNCX)
Quince Therapeutics (QNCX) said Echo Lake Capital has proposed to acquire the company's common stock at $1.60 per share in cash
